Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412542 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00412542: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00412542 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00412542, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas. 1.2 To determine the rate of measureable clinical response in patients treated with Thalidomide and CPT-11. 1.3 To determine Thrombotic thrombocytopenic purpura (TTP), overall survival and unexpected toxicity of Thalidomide and CPT-11 used in recurrent malignant gliomas. 1.4 To determine changes in dynamic magnetic resonance imaging (MRI) as a surrogate marker for treatment effect.
Interventions
- PROCEDURE MRI Scan
- DRUG Thalidomide
- DRUG CPT-11
- PROCEDURE Quantitative Sensory Tests (QST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412542
The ClinicalTrials.gov registry entry for NCT00412542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MRI Scan is the first listed.
NCT00412542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412542 about?
NCT00412542 is a clinical study titled "Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas". Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas. 1.2 To determine the rate of measureable clinical response in patients tre...
What is the current status of trial NCT00412542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2003-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00412542?
The interventions under investigation include: MRI Scan (PROCEDURE), Thalidomide (DRUG), CPT-11 (DRUG), Quantitative Sensory Tests (QST) (PROCEDURE).
Who is sponsoring clinical trial NCT00412542?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.